drugset / Trial / NCT01511029

Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)

NCT01511029

Phase 1 Completed 68 enrolled Knopp Biosciences
RandomizedCrossoverDouble-blindTreatment

Summary

To evaluate whether dexpramipexole prolongs the QTc interval when orally administered to healthy volunteers.

Timeline

Start
2012-01
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexpramipexole Small molecule 300 mg Oral
Subject Dexpramipexole Small molecule 600 mg Oral
Comparator Moxifloxacin Small molecule 400 mg Oral